



# Relieving Companion Animals from Chronic Inflammatory diseases – 1<sup>st</sup> Osteo Arthritis

A Strategic Investment Opportunity

September 2025



# Chronic Inflammatory Diseases

Current treatments are inadequate for managing chronic diseases



- **Osteoarthritis** : 13%-20% of dogs and 50% of horses
- **Atopic Dermatitis** : 10% of dogs
- **Gingivostomatitis** : 5% of cats
- for which there is **no cure available on the market, only drugs targeting symptoms** (AINS, Mab)
- but these drugs:
  1. generate **side effects**
  2. are **exhausting for pet owners** to respect strict observance
  3. and also prove **very costly** over time, up to 1 500€ / year for pet owners

**\$10Bn**


**Pet-Drug Market**



**our best friends deserve safe, convenient  
and affordable solutions!**



# Our solutions : Neonatal Stem Cells



1. **Restore** joint immune balance
2. **Control** joint inflammation/pain
3. **Reduce** cartilage degradation

Vetbiobank exploits the immunomodulatory power of stem cells to offer a first-line solution to dogs (Livencia®) and horses (Equipren®)

**12**  
month  
efficacy

**No**  
severe side  
effect

**<650€**  
per year for  
dog owners

\* Data provided in the market authorization application

# A unique and scalable proprietary platform with low COG matching mass market demand



## ➤ **Allogeneic Neonatal Mesenchymal Stem Cells**



Patented process

## ➤ the **most scalable** allogeneic stem cell technology on the market:

1. our registered **process is industrialised**
2. products are presented in a **ready-to-use format**
3. and can be conveniently **stored (-20°C) at the clinic** allowing treatment at diagnostic


→ **Competitive COG:**

→ **Improved product's acceptance** by the veterinarians

\* Data provided in the market authorization application



# Competition :

Scale up to reduce Cost and Logistics to fit with vet practices



# Phase III results : Success Rates of Livencia®

Primary endpoint – Total Orthopedic Score at D90



Safety Population

**141**



Intention To Treat  
(ITT)

**125**



# 2024 – Achievements / 2025 – Road Map




Q1 2024

Q2 2024

Q3 2024

Q4 2024



MA dossier Submission  
Europe – LIVENCIA  
canine arthrosis



ANSES Authorization  
France – EQUIPREN  
Equine arthrosis



Inspection  
GMP commercial



Q1 2025

Q2 2025

Q3 2025

Q4 2025

Move to new site  
*Bioserra 3*



Aseptic Process Simulation  
Bioproduction

3 validation batches



ANSES  
Inspection



EMA answers to LoQ  
Europe – Canine  
Arthrosis



EMA answers to LOI  
Europe – Canine  
Arthrosis



LARVOL

# Additional Growth – Geographic expansion & new products launches



Geographical extension of existing products.



Livencia® - canine osteoarthritis

**2029**

**US Market Authorization**

**2033**

New products arising from the platform with initial clinical data in diseases beyond OA



VBX-101 - feline gingivostomatitis

**2029**

**EU Market Authorization**

**2033**

*efficacy pilot study + orphan drug designation*



VBX-101 – canine atopic dermatitis

**2029**

**EU Market Authorization**

**2034**

*safety pilot study*



# 8m€ to make Vetbiobank a profitable structure by 2028



- ✓ to cover digital marketing and commercial opérations
- ✓ to cover costs of clinical services providers and related regulatory fees
- ✓ to **upscale the biomanufacturing unit** by 2026 and 2027
- ✓ **to cover the G&A costs and increase in working capital** during the period



**2028**

**breakeven  
point**

**9.6m€**

revenues  
2030

**4.6m€**

**EBITDA  
2030**

# 4m€ from new investors



Vetbiobank has been **created in 2011 in Lyon** (France) and is supported by **8 employees** today...



**CEO & QP**  
Stéphane Maddens



**COO**  
Nadia Plantier



**CMO**  
Harald Egelhofer



**Ext. CSO**  
Jean Deleforge



...it has been **financed with 11m€** since then, partially **coming from renown BAs and FOs**...



...who will keep supporting **the company's 8m€ investment efforts** until 2028...

**4m€**  
new investors

**1m€ (20%)**  
existing shareholders



**3m€**  
non dilutive funding

...together with **new investors, who can reach** the Vetbiobank adventure **as shareholders, asset acquirers or licensing partners.**



capital raise



M&A



carve out



licensing deal



**4m€**  
**We are open to explore services opportunities**



Nadia Plantier, COO  
[n.plantier@vetbiobank.com](mailto:n.plantier@vetbiobank.com)

